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Abstract 
 
mTOR complex 1 (mTORC1) and p70 S6 kinase 
(S6K1) are both involved in the development of 
obesity-linked insulin resistance. Recently, we 
showed that the S6K1 inhibitor PF-4708671 (PF) 
increases insulin sensitivity. However, we also 
reported that PF can increase glucose metabolism 
even in the absence of insulin in muscle and hepatic 
cells. Here, we further explored the potential 
mechanisms by which PF increases glucose 
metabolism in muscle and liver cells independently 
of insulin. Time-course experiments revealed that 
PF induces AMP-activated protein kinase (AMPK) 
activation before inhibiting S6K1. However, PF-
induced glucose uptake was not prevented in 
primary muscle cells from AMPK α1/2 double-KO 
(dKO) mice. Moreover, PF-mediated suppression 
of hepatic glucose production was maintained in 
hepatocytes derived from the AMPK α1/2–dKO 
mice. Remarkably, PF could still reduce glucose 
production and activate AMPK in hepatocytes from 
S6K1/2-dKO mice. Mechanistically, bioenergetics 
experiments revealed that PF reduces 
mitochondrial complex I activity in both muscle 
and hepatic cells. The stimulatory effect of PF on 
glucose uptake was partially reduced by expression 
of the Saccharomyces cerevisiae NADH: 
ubiquinone oxidoreductase in L6 cells. These 
results indicate that PF-mediated S6K1 inhibition is 
not required for its effect on insulin-independent 
glucose metabolism and AMPK activation. We 
conclude that although PF rapidly activates AMPK, 
its ability to acutely increase glucose uptake and 
suppress glucose production does not require 
AMPK activation. Unexpectedly, PF rapidly 
inhibits mitochondrial complex I activity, a 
mechanism that partially underlies PF’s effect on 
glucose metabolism.  
 
The mechanistic target of rapamycin (mTOR) 
complex 1 (mTORC1) and its downstream effector 
p70 ribosomal S6 kinase (S6K1) are important 
modulators of energy homeostasis (1,2). This 
pathway regulates cell proliferation, growth and 
protein synthesis, which are tightly regulated 
depending on substrate availability (3). 
Furthermore, the mTORC1/S6K1 pathway also 
acts as an energy sensor by sensing amino acids, 
lipids and energy status and triggers a negative 
feedback loop towards the PI3K/Akt pathway to 
terminate its activation after insulin or growth 
factor stimulation (4-7). However, this negative 
feedback loop is overactivated by nutrient satiation 
in metabolic diseases such as obesity contributing 
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to the development of insulin resistance and type 2 
diabetes (7-9). Therefore, targeting downstream 
effectors of mTORC1 such as S6K1 might be a 
promising strategy to improve the metabolic 
syndrome.  
 
We have previously shown that pharmacologic 
inhibition of S6K1 using PF-4708671 (PF) 
improved glucose tolerance in mice fed high-fat 
diet by restoring insulin-induced Akt 
phosphorylation in obese mice (10). Furthermore, 
in vitro studies using L6 myocytes and FAO 
hepatoma cells revealed the ability of PF to increase 
basal muscle glucose uptake and to decrease basal 
hepatic glucose production (10). These results were 
obtained in the absence of insulin stimulation 
suggesting an additional mechanism of this 
compound to modulate energy homeostasis 
independently from enhancing insulin signaling. 
Previously, several studies have shown a role of 
S6K to regulate AMPK (adenosine 5’ 
monophosphate activated protein kinase) which is 
known to be important for energy homeostasis. 
Indeed, S6K has been shown to phosphorylate 
AMPK on Ser 491 in neurons, inhibiting its activity 
(11). In addition, selective S6K1/2 deletion in 
muscle is associated with an increase in AMPK 
activity due to an increase of the AMP/ATP ratio 
(12) suggesting that S6K may participate in the 
inhibition of AMPK by either a direct and/or 
indirect mechanisms. However, a previous study 
using mouse embryonic fibroblasts derived from 
S6K1/2 KO mice showed that PF activates AMPK 
independently of S6K1 inhibition (13). AMPK is an 
important regulator of energy homeostasis by 
sensing the energy level via the AMP/ATP ratio 
thus activating catabolic processes to provide 
energy to the cells. AMPK activation induces 
glucose uptake, fatty acid oxidation, autophagy and 
inhibits cell growth and protein synthesis (14-16). 
However, it remains unknown whether the insulin-
independent effect of PF on glucose metabolism are 
linked to either S6K1 inhibition or AMPK 
activation in skeletal muscle and liver, the principal 
sites of glucose disposal. 
 
In this paper, we thus explored the mechanisms 
behind the changes in glucose metabolism in 
muscle and hepatic cells upon S6K1 inhibition 
independently of insulin stimulation. We evaluated 
the contribution of S6K1, AMPK and 
mitochondrial function to PF-4708671-mediated 
glucose uptake in muscle cells and decreased basal 
glucose production in hepatocytes. In both muscle 
cells and hepatocytes, we observed that PF-
4708671 increases both AMPK Thr172 and ACC 
Ser79 phosphorylation reflecting an increase in 
AMPK activity. We next used primary muscle and 
liver cells derived from AMPK α1/2 dKO and 
S6K1/2 dKO mice to determine the role of both 
AMPK and S6K in the glucose metabolic effect of 
PF-470867. These experiments showed that neither 
AMPK or S6K are required for the acute effect of 
the compound on glucose metabolism. On the other 
hand, we found that PF-4708671 reduces 
mitochondrial complex I activity which is partly 
responsible for its glucose enhancing effect in 
muscle cells. 
 
Results 
 
PF-4708671 rapidly increased AMPK 
phosphorylation before inhibiting S6K1  
We have previously shown that S6K1 is a key 
regulator of glucose disposal in both muscle and 
liver (7,17) and that the S6K1 inhibitor PF-4708671 
(PF) increases both insulin-dependent and insulin-
independent glucose metabolism in muscle and 
hepatic cells (10). However, the effect of PF on 
AMPK activation remains unexplored in 
metabolically relevant cellular models. As shown in 
Fig. 1A and 1B, dose-response experiments showed 
that acute (2h) PF treatment (1 to 20 µM) increases 
phosphorylation of AMPK on Thr172 in both L6 
myocytes and FAO hepatocytes. The drug also 
enhanced the phosphorylation of the AMPK 
substrate ACC on Ser79. These effects were 
associated with a dose-dependent inhibition of S6 
phosphorylation on Ser 240/44 suggesting that 
S6K1 inhibition by PF led to AMPK activation. 
 
To confirm that S6K1 inhibition is required for 
AMPK activation, we next performed time-course 
experiments (Fig. 1C-D). Unexpectedly, AMPK 
Thr172 and ACC Ser79 phosphorylation were 
already robustly increased 5 min after PF treatment 
while S6 phosphorylation was only found to be 
reduced at least 30 min after PF exposure in L6 cells 
(Fig. 1C) and FAO cells (Fig. 1D). These results 
indicate that AMPK activation by PF precedes 
S6K1 inhibition and further suggest that rapid 
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AMPK activation may contribute to PF action on 
glucose metabolism in muscle and liver cells. 
 
PF-4708671 increased glucose uptake in muscle 
cell and decreased hepatic glucose production 
independently from AMPK 
Since AMPK is a key regulator of muscle glucose 
uptake (18), we next determined whether the 
induction of glucose uptake by PF was AMPK-
dependent. We used differentiated muscle cells 
from WT mice or mice lacking both AMPKα1 and 
AMPKα2 catalytic subunits (AMPK α1/2 dKO 
muscle cells). After 5 and 48 h of treatment with 
PF, AMPK phosphorylation on Thr172 and ACC 
phosphorylation on Ser79 were increased in 
differentiated WT myocytes but, as expected, not in 
AMPK α1/2 dKO muscle cells (Fig. 2A). In both 
AMPK WT and dKO muscle cells, PF treatment 
decreased basal and insulin-stimulated S6 
phosphorylation in both WT and AMPK α1/2 dKO 
muscle cells. PF treatment of both WT and AMPK 
α1/2 dKO muscle cells for 5 and 48 h increased 
glucose uptake, compared to vehicle treated cells 
(Fig. 2B). However, lack of AMPK activation did 
not reduce the stimulatory effects of PF treatment 
on muscle glucose uptake. These data demonstrate 
that AMPK is dispensable for the stimulatory effect 
of PF on muscle glucose uptake.  
 
To further investigate the role of AMPK in the PF-
induced suppression of hepatic glucose production 
(HGP), we next isolated hepatocytes from WT mice 
or mice lacking both AMPKα1 and AMPKα2 
catalytic subunits (AMPK α1/2 dKO hepatocytes). 
As expected, western blot analysis confirmed that 
AMPK α1/2 dKO hepatocytes did not express 
AMPK (Fig. 2C). In WT hepatocytes, PF increased 
both AMPK phosphorylation on Thr172 and ACC 
phosphorylation on Ser79 without (left panel) or 
with (right panel) glucagon incubation (Fig 2C).  In 
addition, PF dose-dependently inhibited S6 
phosphorylation in both AMPK WT and α1/2 dKO 
hepatocytes. As a positive control, we used 
metformin which increased AMPK and ACC 
phosphorylation with or without glucagon (Fig. 
2C). Interestingly, metformin did not affect S6 
phosphorylation in WT hepatocytes but decreased 
S6 phosphorylation in AMPK α1/2 double KO 
hepatocytes (Fig. 2C).  
 
We next determined HGP in primary hepatocytes in 
basal and glucagon-stimulated conditions (Fig.2 
D). As reported previously (19), AMPK is not 
required for basal or glucagon-induced HGP. 
Inhibition of S6K1 with PF (20 µM) was found to 
reduce basal and glucagon-stimulated HGP in 
AMPK WT and this response was amplified in α1/2 
dKO hepatocytes, especially in the glucagon-
stimulated state. Similar results were obtained 
using metformin, which was found to blunt HGP 
even more in α1/2 dKO than in WT hepatocytes, in 
agreement with a previous report (19). These results 
indicate that AMPK is also dispensable for the 
inhibitory effect of PF on hepatic glucose 
production.  
 
PF-4708671 decreased basal hepatic production 
independently from S6K1 
To determine whether PF-mediated inhibition of 
HGP was S6K1-dependent, we next isolated 
hepatocytes from S6K1/2 double KO mice. As 
anticipated, S6K1 expression was absent in S6K1/2 
dKO hepatocytes and PF decreased S6 
phosphorylation in WT hepatic cells (Fig. 3A). In 
addition, PF increased AMPK and ACC 
phosphorylation in both S6K1/2 WT and double 
KO hepatocytes suggesting that S6K1 is 
dispensable for PF-induced AMPK activation (Fig. 
3A). Similarly, metformin strongly increased 
AMPK and ACC phosphorylation in both WT and 
S6K1/2 dKO hepatocytes but did not affect S6 
phosphorylation in WT hepatocytes (Fig. 3A). In 
both WT and S6K1/2 dKO hepatocytes, PF (20 
µM) decreased glucagon-stimulated HGP (Fig. 
3B). Metformin also decreased HGP with no 
differences between S6K1/2 WT and double KO 
hepatocytes. Thus, neither AMPK nor S6K is 
required for the ability of PF to blunt glucose 
production in hepatocytes. 
 
PF-4708671 decreased mitochondrial 
respiration and mitochondrial spare respiratory 
capacity in muscle cells and hepatocytes.  
Since metformin has been previously shown to 
control glucose production through regulation of 
hepatic energy state and inhibition of mitochondrial 
respiration (19-21) we next investigated whether PF 
could exert its glucose metabolic effects through a 
similar mechanism. Using a Seahorse XF 24 system 
to determine mitochondrial respiratory parameters 
(Fig. 4A), we next examined the effect of PF on 
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oxygen consumption in L6 myotubes and FAO 
hepatocytes. Cells were first treated with PF (1-20 
µM) for 400 min to determine the maximal effect 
of the compound on basal respiration and whether 
this effect could be sustained over time. In L6 cells, 
there was a trend for PF to reduce basal 
mitochondrial respiration (Fig. 4 B-C) which was 
more apparent in FAO cells, as well as respiration 
associated with ATP production at 20 µM (Fig. 4 
D-E). In addition, PF lowered the maximal 
respiration and the spare respiratory capacity in 
both L6 and FAO cells. These results indicate that 
PF reduced mitochondrial respiratory capacity in 
both cell types.  
 
PF-4708671 reduced mitochondrial complex 1 
activity 
We then assessed whether this decrease in maximal 
respiratory capacity was due to a decrease in 
mitochondrial complexes I and/or II activity. Cells 
were permeabilized to allow ADP, pyruvate (Pyr), 
malate (Mal) and succinate (Succ) to pass through 
the plasma membrane and to reach mitochondria. 
L6 cells were acutely treated with different 
concentrations of PF (i.e. drug added just before the 
assay) and the plate was added in the Seahorse XF 
24 system. Addition of Pyr/Mal in the presence of 
ADP increased mitochondrial complex I activity 
which was dose-dependently inhibited by PF (Fig. 
5A). Mitochondrial complex II activity was 
measured by adding the complex I inhibitor 
rotenone first, followed by succinate. No significant 
effect of PF treatment was observed on 
mitochondrial complex II activity (Fig. 5B). Similar 
results were obtained in FAO cells. Indeed, PF 
reduced mitochondrial complex I activity in hepatic 
cells but failed to affect mitochondrial complex II 
activity (Fig. 5C-D). Taken together, these results 
show that PF acts mainly on mitochondrial complex 
1 to regulate mitochondrial function in both muscle 
and hepatic cells.  
 
PF-inducing glucose uptake is partially 
dependent of mitochondrial complex 1 activity.     
To determine the role of mitochondrial complex I 
in mediating glucose uptake in L6 myocytes, we 
stably expressed the Saccharomyces cerevisiae 
NADH:ubiquinone oxidoreductase (NDI1) in these 
cells, which can maintain respiration even in the 
presence of complex-I inhibitors (22-25) . 
Expression of NDI1 in muscle cells (Fig. 6A) was 
found to significantly reduce PF-mediated glucose 
uptake without interfering with insulin-induced 
glucose disposal in these cells (Fig. 6B). When 
taking into account the changes in basal glucose 
uptake in NDI1-expressing cells in order to 
calculate the specific effect of PF on this parameter, 
we conclude that about 45% of the drug effect may 
be accounted by inhibition of mitochondrial 
complex 1 activity in muscle cells (Fig. 6C). These 
results demonstrate that PF increases insulin-
independent glucose uptake at least in part by 
inhibition of mitochondrial complex 1 activity in 
muscle cells but that other unknown mechanism(s) 
are also involved.  
 
Discussion 
 
We recently reported that pharmacologic inhibition 
of S6K1 by PF for only one week improves glucose 
tolerance in high-fat fed obese mice and increases 
insulin-induced Akt phosphorylation in liver, 
muscle and white adipose tissue (10). Interestingly, 
these studies also revealed that PF enhances basal 
glucose uptake in myocytes and decreases basal 
glucose production in hepatocytes suggesting that 
the S6K1 inhibitor also modulates glucose 
metabolism through insulin-independent pathways. 
This is consistent with other studies in C2C12 cells 
where transfection of a siRNA targeting S6K1 also 
enhanced basal glucose uptake (26). In the present 
study we found that PF rapidly modulate glucose 
metabolism in both L6 myotubes and FAO 
hepatocytes in association with increased 
phosphorylation of AMPK and its downstream 
effector ACC.  
 
However, following acute PF treatment, we 
observed an increase in both AMPK Thr172 and 
ACC Ser79 phosphorylation, a well-known 
substrate of active AMPK. The time-course 
experiment performed in PF treated cells revealed 
that AMPK is activated rapidly (Thr172 AMPK and 
Ser79 ACC phosphorylation), faster than PF-
mediating S6K1 inhibition. Despite this rapid 
increase in AMPK activation, we showed that PF-
regulating glucose homeostasis is independent from 
AMPK. Thus, ruling out a potential role of AMPK 
on PF-stimulating glucose uptake and decreasing 
hepatic glucose production. These results are also 
supported by other studies showing that AMPK 
deficiency failed to impact hepatic glucose 
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production and the suppressive effect of metformin 
on this process (19,27).   
 
PF has been previously suggested to activate 
AMPK by inhibiting mitochondrial complex I of 
the respiratory chain independently of S6K1 in 
mouse embryonic fibroblasts (13). Using muscle 
cells and hepatocytes, we also observed that PF 
acutely decreased mitochondrial complex I activity 
suggesting that the drug modulates glucose 
metabolism in these cells through inhibition of 
mitochondrial function. Using S6K1/2 dKO hepatic 
cells, we further showed that PF inhibits basal or 
glucagon-stimulated hepatic glucose production 
independently from S6K. These results suggest that 
PF action on hepatic glucose production is 
dispensable from S6K inhibition and thus might be 
entirely due to a higher energy demand and 
metabolism rewiring towards replenishing acetyl-
CoA pools caused by lower mitochondrial complex 
I activity. 
 
Glucose uptake can be attributed to glucose 
transport, glucose oxidation and glycogen 
synthesis. Our respirometry analysis revealed that 
PF decreased OXPHOS suggesting that reduction 
in mitochondrial ATP production might have 
induced glucose transport for ATP production from 
glycolysis. Reduction of mitochondrial complex 1 
activity explains, in part, the insulin-independent 
action of PF on glucose metabolism. In L6 muscle 
cells, the ability of PF to enhance glucose uptake 
was partially reversed by stable NDI1 expression, 
indicating that the decrease of mitochondrial 
complex 1 activity contributes to the stimulatory 
effect of the compound on muscle glucose uptake. 
This conclusion is also supported by previous 
studies showing that inhibition of mitochondrial 
complex 1 by a very low dose of rotenone or 
siRNA-mediated silencing of NADH:Ubiquinone 
Oxidoreductase Subunit A13, a subunit of complex 
I, can reduce hepatic glucose production and 
stimulate glucose consumption in muscle cells, 
independently of AMPK (28). In addition, other 
studies have reported similar mechanisms. Indeed, 
berberine has been shown to enhance glucose 
utilization and glycolysis by reducing 
mitochondrial glucose oxidation in L6 myotubes. 
Altogether, our results suggest that the energy 
demand generated by the inhibition of 
mitochondrial complex 1 activity is enough to drive 
glucose uptake in muscle and to decrease hepatic 
glucose production in PF-treated cells, 
independently from AMPK activation. However, 
the finding that stable expression of NDI1 only 
partially blunted PF-inducing glucose uptake in 
muscle cells suggests that other mechanism(s) such 
as S6K1 inhibition may also contribute to the 
insulin-independent metabolic effect of the drug. 
 
This dual effect of PF-4708671 might be an 
interesting advantage to treat type 2 diabetes more 
efficiently. We found that part of the action of PF-
4708671 is by inhibiting mitochondrial complex 1, 
which is also a well-known target for the most 
prescribed type 2 diabetes drug, metformin (20,29). 
These results suggest that PF might reproduce 
many beneficial effects mediated by metformin in 
addition to those associated with S6K1 inhibition 
such as direct inhibition of the negative feedback 
loop regulating insulin signaling. Metformin’s 
ability to blunt hepatic glucose production is also 
independent of AMPK and rather mediated by 
inhibition of mitochondrial complex 1 (20) and  
mitochondrial glycerol-phosphate dehydrogenase 
(19,30).  
 
Conclusions 
PF-4708671 was characterized as a selective S6K1 
inhibitor, but our study and others demonstrate it 
also has S6K1-independent effects, notably by 
reducing mitochondrial complex I activity. This 
inhibition led to a rapid, but transient induction, of 
AMPK activation and ACC inhibition, followed by 
S6K1 inhibition in muscle cells and hepatocytes. 
While S6K1 inhibition by this drug restored insulin 
signaling in cells and tissues from obese insulin-
resistant mice (10), the present data reveal that PF 
also regulates glucose metabolism independently 
from AMPK by reducing mitochondrial complex 1 
activity. These results suggest that PF might 
represent an interesting therapeutic tool since it can 
both reverse S6K1-mediated insulin resistance (10) 
as well as improving glucose control through 
inhibition of mitochondrial respiration, thus 
combining two key mechanisms that are well 
recognized for the treatment of type 2 diabetes.  
 
Experimental procedures 
 
Reagents and antibodies. DMSO was from 
Sigma-Aldrich (St. Louis, MO, USA). PF-4708671 
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was from Cayman (Ann Harbor, Michigan, USA). 
Insulin was from Eli Lilly (Toronto, ON, Canada). 
The phospho-S6 Ser 240/44, S6, phospho-AMPK 
Thr172, phospho-AMPK Ser491, AMPK, 
phospho-ACC Ser79, ACC, phosphor-S6K1 
Thr389, S6K1 antibodies were from Cell Signaling 
Technologies (Danvers, MA, USA). The anti-actin 
antibody was from Millipore (St. Louis, MO, 
USA). Antibodies from Cell Signaling Technology 
were used at 1:1,000 dilution. Actin antibody was 
used at 1:10,000 dilution. 
 
Animals. 
All animal studies were approved by the Paris 
Descartes University ethics committee (no. 
CEEA34.BV.157.12) and the Direction 
Départementale des Services Vétérinaires of the 
Préfecture de Police de Paris authorization no. 75-
886). All mice were maintained in a barrier facility 
under a 12-h light/12-h dark cycle (8 am-8 pm) with 
free access to water and standard diet. Liver double-
knockout of AMPKα1 and AMPKα2 catalytic 
subunits was achieved by crossing AMPKα1lox/lox 
mice with AMPKα2lox/lox mice and then Alfp-Cre 
transgenic mice (31,32) on C57BL/6 background, 
to generate AMPKα1 lox/lox, α2lox/lox (control) and 
AMPKα1 lox/lox, α2lox/lox-Alfp-Cre (liver AMPK 
α1/2 dKO mice). S6K double knockout or S6K wild 
type mice were a kind gift of Mario Pende (Inserm, 
Paris, France). The S6K1/2 dKO mice were 
generated as previously described (33). 
 
Cell culture. 
 
Rat L6 myoblasts were grown in α-MEM 
(Invitrogen, Burlington, ON, Canada) 
supplemented with 10% FBS (vol./vol.). L6 
myoblasts were differentiated into myotubes in α-
MEM with 2% (vol./vol.) FBS as previously 
described (34). FAO rat hepatocytes were 
maintained in RPMI media (Invitrogen) and 
supplemented with 10% (vol./vol.) FBS.  Wild-type 
(WT) and AMPK α1/2 double knock-out (KO) 
primary muscle cells were grown as reported 
previously (35).   
 
NDI1 expression in L6 cells. The pMXS-NDI1 
(NADH:ubiquinone oxidoreductase) plasmid was a 
gift from David Sabatini (Addgene plasmid 
#72876) and the pMXS-control vector was kindly 
provided by Kivanc Birsoy (Rockefeller 
University, USA). Plasmids were amplified as 
previously described in Phoenix-Eco cells (ATCC 
#CRL-3214) (28). Undifferentiated rat L6 
myoblasts were infected with the amplified 
retrovirus and selected with 5 µg/ml of blasticidin 
to generate L6-pMXS and L6-NDI1 stably 
transfected myoblasts. Both L6 cell lines were then 
differentiated into myotubes as described in the 
previous section creating cell lines that stably 
overexpress NDI1 or the control vector. NDI1 
overexpression was verified by purifying total RNA 
using the GeneJet RNA purification kit (Thermo 
Scientific, Burlington, ON, Canada) followed by 
the RNA reverse transcription with a High Capacity 
cDNA Reverse Transcription Kit from Applied 
Biosystems (Burlington, ON, Canada). Real-time 
PCR was performed using SYBR Green Jump-Start 
Expression Kit (Sigma-Aldrich, Oakville, ON, 
Canada). Three sets of primers for S. cerevisiae 
NDI1 were used (5’→3’) (IDT, Skokie, IL, USA). 
NDI1 set 1: F-TCAAAGTACATCTGAGA 
ACGG, R-GTCTTTGCCAACAATTGCT. NDI1 
set 2: F-GCTTAATGACCTTCTAC TTATGGAG, 
R-GATCTTGCAGATAGAA TCATGGAC. NDI1 
set 3: F-CTTTGTTA CCTTCTGCACCA, R-
ACGATGGGCTCAA TAATTGAC. Gene 
expression was assessed by the ΔΔCt method and 
the rat Arbp was used as the reference gene (F-
TAAAGACTGGA GACAAGGTG, R-
GTGTAGTCAGTCTCCA CAGA).  
 
Mouse primary hepatocytes. Mouse primary 
hepatocytes were isolated from 10-week-old male 
mice by a modified version of the collagenase 
method as described previously (19). Wild-type 
(WT), AMPK α1/2 double KO and S6K1/2 double 
KO primary hepatocytes were plated in M199 
medium supplemented with 100 U/ml penicillin, 
100 μg/ml streptomycin, 0.1% bovine serum 
albumin, 500 nM dexamethasone (dex; Sigma-
Aldrich), 100 nM triiodothyronine (Sigma-
Aldrich), 10 nM insulin (Actrapid, Novo Nordisk), 
at a density of 2.5 × 105 cells/well on 6-well plates. 
After attachment (3–4 hours), hepatocytes were 
maintained in M199 medium with antibiotics and 
100 nM dexamethasone for 16 hours, followed by 
drug treatment as described below. Vehicle 
(dimethyl sulfoxide, DMSO 0.02% [vol./vol.]) or 
PF-4708671 was used at the indicated doses.  
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Western blotting. Western blots were performed 
as described (36). Briefly, equal amounts of 
proteins were separated by SDS-PAGE (9 % 
[wt/vol.]) and transferred onto nitrocellulose 
membranes. Membranes were blocked in 5% 
(wt/vol.) milk diluted in 50 mM Tris pH 7.4, 0.1% 
(vol./vol.) Tween (TBS-T) and incubated overnight 
at 4°C with the respective antibodies diluted in 3% 
(wt/vol.) BSA in TBS-T. 
 
Glucose uptake. L6 cells were serum-deprived for 
5 h prior to the experiments, and 100 nmol/l of 
insulin was used to stimulate the cells during the 
last hour of deprivation. L6 cells were incubated for 
8 min in HEPES-buffered saline containing 10 
µmol/l unlabeled 2-DG and 10 µmol/l D-2-deoxy-
[3H] glucose (0.5 µCi/ml). The reaction was 
terminated by washing three times with ice-cold 
0.9% NaCl (wt/vol). Cell-associated radioactivity 
was determined by lysing the cells with 0.05 N 
NaOH, followed by liquid scintillation counting 
and normalization to protein concentration.  
 
Glucose production. FAO cells were incubated 16 
h in serum-free medium, with or without the 
indicated concentration of insulin, PF-4708671 (10 
µmol/l). The cells were washed three times with 
PBS and incubated with phenol- and glucose-free 
DMEM medium supplemented with 20 mmol/l 
sodium L-lactate and 2 mmol/l sodium pyruvate for 
5 h with or without the indicated concentration of 
insulin and PF-4708671 (10 µmol/l). Cell 
supernatants were collected, and glucose 
concentration was measured with the Amplex-Red 
Glucose assay kit (Invitrogen, Burlington, ON, 
Canada) according to the manufacturer’s 
instructions. Cells were lysed with 50 mmol/l 
NaOH and protein concentration was determined 
using a BCA protein assay kit for normalization.  
Primary mouse hepatocytes on 6-well plates (2.5 × 
105 cells/well) were maintained in M199 medium 
containing antibiotics and 100 nM dex for 16 hours 
prior to the measurement of glucose production. 
Hepatocytes were washed once with PBS, and 
glucose production was determined after an 8-hour 
incubation period in glucose-free DMEM 
containing lactate/pyruvate (10:1 mM) and 100 nM 
dex alone or with glucagon 25 nM (Sigma-Aldrich) 
and with various doses PF-4708671. Glucose 
concentration values were corrected by protein 
content. 
 
XF metabolic assay 
Oxygen consumption rate (OCR) measurements 
were made using the Seahorse XF24 Extracellular 
Flux Analyzer. For mitochondrial metabolic 
parameters, we used successively different 
concentration (1-20 µM) of acute PF-4708671, 
oligomycin (1 µM), FCCP (2 µM), rotenone/ 
antimycin (1 µM). For determination of complex I 
and complex II activity, cells were pre-incubated in 
mannitol/sucrose (MAS) buffer free of any 
substrate but containing 4 mM ADP for 30 min 
followed by the addition of XF PMP permeabilizer 
agent (1 nM) just before adding the plate in the 
XF24. Pyruvate/malate followed by rotenone (1 
µM), succinate (10 mM) and antimycin (1 µM) 
were injected to the cells.  
 
Quantification and statistical analyses. One- and 
two-way ANOVA with Newman–Keuls post hoc 
was performed with Sigma Plot version 12 (Systat 
Software, San Jose, CA, USA); p values were 
considered significant if they were <0.05. SDs are 
represented in the graphs.  
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Figure 1: PF-4708671 rapidly increased AMPK phosphorylation before inhibiting S6K1. 
(A) L6 differentiated myocytes and (B) FAO hepatoma cells were treated with the indicated concentrations 
of PF-4708671 for 2 hours in presence of FBS 10%. Cells were then harvested, processed for SDS-PAGE 
and western blot using the indicated antibodies. (C) L6 differentiated myocytes and (D) FAO hepatoma 
cells were treated for the indicated time with 10 µM PF in presence of FBS 10%. Actin levels are presented 
as loading control.  PF, PF-4708671. *p<0.05, **p<0.01, ***p<0.001 vs vehicle treated cells, as indicated. 
Shown are representative blots and mean +/- SD from 3-5 independent experiments. 
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Figure 2: PF-4708671 did not increase glucose uptake or decreased hepatic glucose production by 
activating AMPK
(A) WT and AMPK α1/2 KO primary muscle cells in absence or presence of insulin (100 nM, 45 min) 
and/or PF-4708671 (10 µM, 5 or 48 h) were lysed and immunoblotting using the indicated antibodies. (B) 
Glucose uptake was assessed in similar conditions. a; p<0.05, vs vehicle treated WT cell, b; p<0.05, vs 
vehicle treated AMPK α1/2 KO cells, c; p<0.05, vs vehicle treated WT cells with insulin, d; p<0.05, vs 
vehicle treated AMPK α1/2 KO cells with insulin. White bar: AMPK α1/2 WT Grey bar: AMPK α1/2 KO 
(C) Hepatocytes were isolated from WT and AMPK α1/2 KO mice and after two days, the cells were 
treated with PF-4708671 (10 µM), metformin (0.5 mM) and/or glucagon (25 nM) for 8h in the hepatic 
glucose production media followed by cell lysis for immunoblotting using the indicated antibodies and (D) 
hepatic glucose production was assessed. PF, PF-4708671. Met, Metformin. White bar: AMPK α1/2 WT 
Grey bar: AMPK α1/2 KO . Glucose value were corrected for protein content. Shown are the mean +/- SD 
of 3-4 independent experiments and representative blot from 3 independent experiments. a; p<0.05, vs 
vehicle treated WT cells without glucagon, b; p<0.05, vs vehicle treated AMPK α1/2 KO cells without 
glucagon, c; p<0.05, vs vehicle treated WT cells with glucagon, d; p<0.05, vs vehicle treated AMPK α1/2 
KO cells with glucagon.
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Figure 3: PF-4708671 decreased basal hepatic glucose 
production in S6K1/2 deficient hepatocytes
(A) Hepatic glucose production was assessed in primary 
hepatocytes culture isolated from WT and S6K1 1/2 KO mice. 
After two days, the cells were treated with PF-4708671 (10 µM), 
metformin (0.5 mM) and/or glucagon (25 nM) for 8h in the HGP 
media followed by cell lysis and immunoblotting using the 
indicated antibodies. PF, PF-4708671. Met, Metformin. (B) 
Glucose produced by the hepatocytes was measured and values 
were corrected for protein content. White bar S6K1/2 WT, Grey 
bar S6K1/2 KO. Shown are the mean +/- SD of at least 4 
independent experiments and representative blot from 3 
independent experiments. a; p<0.05, vs vehicle treated WT cells 
without glucagon, b; p<0.05, vs vehicle treated S6K 1/2 KO cells 
without glucagon, c; p<0.05, vs vehicle treated WT cells with 
glucagon, d; p<0.05, vs vehicle treated S6K 1/2 KO cells with 
glucagon.
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Figure 4: PF-4708671 decreased mitochondrial respiration and mitochondrial spare respiratory 
capacity in muscle cells and hepatocytes. 
L6 cells were seeded at 20,000 cells per well in 24-well XF plates and incubated for 24 hours with 10% 
bovine growth serum (BGS) in MEM at 37ºC/5% CO2 incubator. For differentiation, growth media was 
replaced with differentiation media (2% BGS in MEM). Well differentiated myocytes were used at day 5 
for all assays. (A) Mitochondrial parameters determined from the oxygen consumption trace following 
PF, oligomycin, FCCP and Rotenone/Antimycin A injection. (B-C) L6 cells were acutely treated with 
1-20 μM PF-4708671 by using a port from the seahorse cartridge followed by a Mitostress protocol. 
(D-E) FAO cells were seeded at 20,000 cells per well in 24-well XF plates and incubated for 3 days with 
10% bovine growth serum (BGS) in MEM at 37ºC/5% CO2 incubator. Mitochondrial parameters were 
assessed with the Mitostress protocol and PF acute is the decrease in basal respiration induced by PF after 
400min. *p<0.05, **p<0.01, ***p<0.001 vs vehicle treated cells, as indicated. PF, PF-4708671. Shown 
are the mean +/- SD of 4-5 independent experiments. 
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Figure 5: PF-4708671 reduced mitochondrial complex 1 activity.
On the day of experiment, cells were washed 2 times with MAS buffer containing 4mM ADP and 
treated with the indicated PF-4708671 concentrations before cell permeabilization with XF plasma 
membrane permeabilizer (1 nM) from Seahorse Bioscience. Then the plate was inserted into the XF 
24-well apparatus. Mitochondrial complex I and II activity were assessed by adding successively 
Pyruvate/Malate (Pyr/Mal; 10mM/1mM), Rotenone (Rot; 1 uM), Succinate (10 mM) and Antimycin 
A (AA; 1 uM) in differentiated (A) L6 cells  and (C) FAO hepatocytes. (B-D) Mitochondrial 
complex I activity was calculated from OCR differences between Pyruvate/Malate and Rotenone. 
Mitochondrial complex II activity was calculated from OCR differences between Succinate and 
Antimycin A for. *p<0.05, **p<0.01 vs vehicle treated cells, as indicated. Shown are the mean +/- 
SD of 4-5 independent experiments. 
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Figure 6: PF-inducing glucose uptake is partially blocked by NDI1 expression in 
L6 myotubes    
Stable L6-pMXS and L6-NDI1 (NADH:ubiquinone oxidoreductase) transfected 
myoblasts were differentiated as described in method. NDI1 overexpression was 
verified by purifying total RNA followed by the RNA reverse transcription. (A) 
Real-time PCR was then performed and NDI1 expression was corrected to ARBP 
gene expression. N.D.: Not-detected. (B) Glucose uptake was measured in L6 cell 
transfected with either control vector pMXS or NDI1 and then differentiated. Cells 
were treated with 10 μM PF for 5h and/or with insulin (100 nM, 45 min). White bar: 
pMXS, Grey bar: NDI1 (C) Changes in glucose uptake were corrected for basal 
glucose uptake level in respective conditions and reported in %. White bar: pMXS, 
Grey bar: NDI1. *** p<0.001 vs respective PF-treated pMXS cells, a, b p<0.001 vs 
respective basal, PF, PF-4708671. Shown are the mean +/- SD of 4 independent 
experiments. 
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